转录因子腺病毒E4启动子结合蛋白4在肿瘤中的研究进展

张雪莹; 王亮; 李华男

doi:10.7619/jcmp.20222841

转录因子腺病毒E4启动子结合蛋白4在肿瘤中的研究进展

张雪莹^{1, 2},
王亮^{1, 2},
李华男^{1, 2, ,}

1.
扬州大学医学院, 江苏扬州, 225009
2.
江苏省非编码RNA基础与临床转化重点实验室, 江苏扬州, 225009

基金项目:

国家自然科学基金资助项目 32100911

江苏省高等学校自然科学研究面上项目 20KJB310002

详细信息

通讯作者:
李华男, E-mail: hnli@yzu.edu.cn

中图分类号: R730.1;Q81
计量
- 文章访问数: 188
- HTML全文浏览量: 104
- PDF下载量: 15
出版历程
- 收稿日期: 2022-09-10
- 网络出版日期: 2022-12-22

Research progress of transcription factor E4 promoter-binding protein 4 in tumor

ZHANG Xueying^{1, 2},
WANG Liang^{1, 2},
LI Huanan^{1, 2, ,}

1.
Medical College of Yangzhou University, Yangzhou, Jiangsu, 225009
2.
Jiangsu Basic and Clinical Transformation Key Laboratory of Non-coding RNA, Yangzhou, Jiangsu, 225009

摘要

摘要:
腺病毒E4启动子结合蛋白4(E4BP4)是一种含有碱性亮氨酸拉链的转录因子, 在乳腺癌、肺癌、甲状腺癌、结直肠癌等多种恶性肿瘤中高表达，参与肿瘤的发生发展、转移和侵袭，但关于E4BP4在肿瘤研究中的相关综述较少。本文检索并总结相关文献，概述了E4BP4在不同肿瘤发生发展中的作用，为深入研究E4BP4在肿瘤中的作用机制以及基于E4BP4分子治疗靶点的探究提供理论支撑。
- 转录因子腺病毒E4启动子结合蛋白4 /
- 肿瘤 /
- 分子机制 /
- 治疗靶点 /
- 研究进展
Abstract:
E4 promoter-binding protein 4 (E4BP4) is a transcription factor containing alkaline leucine zips, which is highly expressed in breast cancer, lung cancer, thyroid cancer, colorectal cancer and other malignant tumors, and is involved in the occurrence, development, metastasis and invasion of tumors. However, there are few reviews on E4BP4 in tumor research. In this paper, relevant literature was searched and summarized, and the role of E4BP4 in the occurrence and development of different tumors was summarized, so as to provide theoretical support for further study of the mechanism of action of E4BP4 in tumors and exploration of therapeutic targets based on E4BP4 molecules.
- transcription factor E4 promoter-binding protein 4 /
- tumor /
- molecular mechanism /
- therapeutic target /
- research progress

HTML全文

图 1 E4BP4在乳腺癌中的作用机制

下载: 全尺寸图片幻灯片

参考文献(38)

[1]	COWELL I G, SKINNER A, HURST H C. Transcriptional repression by a novel member of the bZIP family of transcription factors[J]. Mol Cell Biol, 1992, 12(7): 3070-3077.
[2]	ZHANG W, ZHANG J, KORNUC M, et al. Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter[J]. Mol Cell Biol, 1995, 15(11): 6055-6063. doi: 10.1128/MCB.15.11.6055
[3]	HURST H C. Transcription factors 1: bZIP proteins[J]. Protein Profile, 1995, 2(2): 101-168.
[4]	WANG Y H, KUANG Z, YU X F, et al. The intestinal microbiota regulates body composition through NFIL3 and the circadian clock[J]. Science, 2017, 357(6354): 912-916. doi: 10.1126/science.aan0677
[5]	VELMURUGAN B K, CHANG R L, MARTHANDAM ASOKAN S, et al. A minireview of E4BP4/NFIL3 in heart failure[J]. J Cell Physiol, 2018, 233(11): 8458-8466. doi: 10.1002/jcp.26790
[6]	LI D, WANG Y D, YANG M X, et al. mTORC1 and mTORC2 coordinate early NK cell development by differentially inducing E4BP4 and T-bet[J]. Cell Death Differ, 2021, 28(6): 1900-1909. doi: 10.1038/s41418-020-00715-6
[7]	HIRAI T, TANAKA K, TOGARI A. Β-adrenergic receptor signaling regulates Ptgs2 by driving circadian gene expression in osteoblasts[J]. J Cell Sci, 2014, 127(Pt 17): 3711-3719.
[8]	YIN J H, ZHANG J, LU Q J. The role of basic leucine zipper transcription factor E4BP4 in the immune system and immune-mediated diseases[J]. Clin Immunol, 2017, 180: 5-10. doi: 10.1016/j.clim.2017.03.013
[9]	王健, 黄哲平, 杨增明, 等. 腺病毒E4启动子结合蛋白-4(E4BP4)基因在小鼠胚胎着床期间子宫组织中的表达[J]. 分子细胞生物学报, 2006, 39(2): 123-131. https://www.cnki.com.cn/Article/CJFDTOTAL-SWSB200602006.htm
[10]	KENIRY M, PIRES M M, MENSE S, et al. Survival factor NFIL3 restricts FOXO-induced gene expression in cancer[J]. Genes Dev, 2013, 27(8): 916-927. doi: 10.1101/gad.214049.113
[11]	QI J J, YU Y, AKILLI ÖZTVRK Ö, et al. New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals[J]. Gut, 2016, 65(10): 1690-1701. doi: 10.1136/gutjnl-2014-307900
[12]	KURIBARA R, KINOSHITA T, MIYAJIMA A, et al. Two distinct interleukin-3-mediated signal pathways, Ras-NFIL3 (E4BP4) and Bcl-xL, regulate the survival of murine pro-B lymphocytes[J]. Mol Cell Biol, 1999, 19(4): 2754-2762. doi: 10.1128/MCB.19.4.2754
[13]	ZHU C, SAKUISHI K, XIAO S, et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction[J]. Nat Commun, 2015, 6: 6072. doi: 10.1038/ncomms7072
[14]	RHODES D R, KALYANA-SUNDARAM S, MAHAVISNO V, et al. Oncomine 3. 0: genes, pathways, and networks in a collection of 18, 000 cancer gene expression profiles[J]. Neoplasia, 2007, 9(2): 166-180.
[15]	LIN S C, LIN C H, SHIH N C, et al. Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling[J]. Oncogene, 2020, 39(2): 385-398. doi: 10.1038/s41388-019-0994-0
[16]	陆宁宁, 邾萍, 马珠月, 等. 乳腺癌患者一级亲属乳腺癌早期筛查的研究进展[J]. 实用临床医药杂志, 2021, 25(22): 129-132. doi: 10.7619/jcmp.20212780
[17]	LIU L, WU S S, YANG Y, et al. SOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation[J]. Cell Biosci, 2016, 6: 24. doi: 10.1186/s13578-016-0091-9
[18]	GOPAL G, RAJA U M, SHIRLEY S, et al. SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer[J]. Cancer Genet, 2013, 206(5): 174-182. doi: 10.1016/j.cancergen.2013.04.005
[19]	RAWAT A, GOPISETTY G, THANGARAJAN R. E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells[J]. Cell Oncol (Dordr), 2014, 37(6): 409-419.
[20]	KARTHIK I P, DESAI P, SUKUMAR S, et al. E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 function through histone methyltransferases[J]. J Biol Chem, 2018, 293(15): 5624-5635. doi: 10.1074/jbc.RA117.000623
[21]	周树伟, 苏蓓蓓, 冯跃庆, 等. 分化型甲状腺癌患者血清基质金属蛋白酶-13表达水平与肺转移的相关性研究[J]. 实用临床医药杂志, 2021, 25(1): 77-80. doi: 10.7619/jcmp.20200593
[22]	ZHOU Q Y, CHEN J, FENG J L, et al. E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin[J]. Cell Death Dis, 2018, 9(10): 987. doi: 10.1038/s41419-018-1001-3
[23]	ZHOU Q Y, CHEN J, FENG J L, et al. SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways[J]. Mol Cell Biochem, 2017, 435(1/2): 87-95.
[24]	CHA S, SIN M J, KIM M J, et al. Involvement of cellular prion protein in invasion and metastasis of lung cancer by inducing treg cell development[J]. Biomolecules, 2021, 11(2): 285. doi: 10.3390/biom11020285
[25]	FRITZMANN J, MORKEL M, BESSER D, et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential[J]. Gastroenterology, 2009, 137(1): 165-175. doi: 10.1053/j.gastro.2009.03.041
[26]	XU J X, XU G P, ZHANG T X, et al. NFIL3 acts as a nuclear factor to increase osteosarcoma progression[J]. Biomed Res Int, 2019, 2019: 4068521.
[27]	LURAIN J R. Pharmacotherapy of gestational trophoblastic disease[J]. Expert Opin Pharmacother, 2003, 4(11): 2005-2017. doi: 10.1517/14656566.4.11.2005
[28]	PENG Z, ZHANG C, ZHOU W J, et al. The STAT3/NFIL3 signaling axis-mediated chemotherapy resistance is reversed by Raddeanin A via inducing apoptosis in choriocarcinoma cells[J]. J Cell Physiol, 2018, 233(7): 5370-5382. doi: 10.1002/jcp.26362
[29]	BEACH J A, NARY L J, HIRAKAWA Y, et al. E4BP4 facilitates glucocorticoid-evoked apoptosis of human leukemic CEM cells via upregulation of Bim[J]. J Mol Signal, 2011, 6(1): 13.
[30]	BEACH J A, NARY L J, HOVANESSIAN R, et al. Correlation of glucocorticoid-mediated E4BP4 upregulation with altered expression of pro-and anti-apoptotic genes in CEM human lymphoblastic leukemia cells[J]. Biochem Biophys Res Commun, 2014, 451(3): 382-388. doi: 10.1016/j.bbrc.2014.07.103
[31]	PRICEMAN S J, KIRZNER J D, NARY L J, et al. Calcium-dependent upregulation of E4BP4 expression correlates with glucocorticoid-evoked apoptosis of human leukemic CEM cells[J]. Biochem Biophys Res Commun, 2006, 344(2): 491-499. doi: 10.1016/j.bbrc.2006.03.169
[32]	NISHIMURA Y, TANAKA T. Calcium-dependent activation of nuclear factor regulated by interleukin 3/adenovirus E4 promoter-binding protein gene expression by calcineurin/nuclear factor of activated T cells and calcium/calmodulin-dependent protein kinase signaling[J]. J Biol Chem, 2001, 276(23): 19921-19928. doi: 10.1074/jbc.M010332200
[33]	DORN D C, KOU C A, PNG K J, et al. The effect of cantharidins on leukemic stem cells[J]. Int J Cancer, 2009, 124(9): 2186-2199. doi: 10.1002/ijc.24157
[34]	YEUNG J, O'SULLIVAN E, HUBANK M, et al. E4BP4 expression is regulated by the t(17; 19)-associated oncoprotein E2A-HLF in pro-B cells[J]. Br J Haematol, 2004, 125(5): 560-567. doi: 10.1111/j.1365-2141.2004.04953.x
[35]	WU S J, LI J Y, CAO M S, et al. A novel integrated gene coexpression analysis approach reveals a prognostic three-transcription-factor signature for glioma molecular subtypes[J]. BMC Syst Biol, 2016, 10(Suppl 3): 71.
[36]	KENIRY M, DEARTH R K, PERSANS M, et al. New frontiers for the NFIL3 bZIP transcription factor in cancer, metabolism and beyond[J]. Discoveries (Craiova), 2014, 2(2): e15.
[37]	UNOKI M, NAKAMURA Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway[J]. Oncogene, 2001, 20(33): 4457-4465.
[38]	SADOWSKI S M, PUSZTASZERI M, BRULHART-MEYNET M C, et al. Identification of differential transcriptional patterns in primary and secondary hyperparathyroidism[J]. J Clin Endocrinol Metab, 2018, 103(6): 2189-2198.